Implementation of circulating tumor DNA (ctDNA) testing in precision oncology: A four-year experience from a tertiary cancer center in India.

ABSTRACT:

Introduction

Liquid biopsy testing has emerged as a pivotal tool in molecular characterization of solid malignancies. Circulating tumor DNA (ctDNA) analysis is quintessential in precision oncology for early detection, disease monitoring, prognosis, and theranostic purposes. This study summarizes ctDNA analysis performed on patients with advanced or metastatic solid tumors at tertiary cancer centers in India (2021-2024).

Methods

ctDNA was isolated following standard pre-analytical protocols and quality control measures. Sequencing was performed using the Oncomine Precision Assay on Thermo Fisher platform and Custom Solid Tumor Panel (SOPHiA Genetics) on Illumina platforms. Variant annotation and clinical interpretation were performed as per ACMG and AMP Guidelines.

Results

SUBMITTER: Joshi P 

PROVIDER: S-EPMC12356032 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature